This panel will provide a comprehensive examination of the evolving landscape of market access and pricing strategies in the wake of the Inflation Reduction Act (IRA), featuring insights from experts across the pharmaceutical industry.
- Disrupting the Status Quo - Panelists will explore how the IRA fundamentally shifts the balance of power in pharmaceutical pricing and market access, highlighting the strategic challenges and opportunities for companies navigating Medicare Part D changes.
- Strategies for adapting business models under the IRA, focusing on new pricing strategies, transparency, and innovation within fiscal constraints.
- An examination of the IRA's impact on innovation and smaller biotech firms, addressing funding, investment, and regulatory challenges.
- Discussion on international market trends and their influence on drug pricing and access strategies.
- Effective strategies for engaging with payers to enhance drug accessibility and affordability in the context of new global policies and economic pressures.
